Journal
ONCOTARGET
Volume 7, Issue 34, Pages 55924-55938Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.10482
Keywords
FGFR3-TACC3 fusion; non-small cell lung cancer; phosphatidylinositol 3-Kinase (PI3K); aneuploidy; glioblastoma multiforme
Categories
Funding
- NCI NIH HHS [P30 CA060553] Funding Source: Medline
Ask authors/readers for more resources
Fibroblast growth factor receptors (FGFR) are transmembrane kinase proteins with growing importance in cancer biology given the frequency of molecular alterations and vast interface with multiple other signaling pathways. Furthermore, numerous FGFR inhibitors in clinical development demonstrate the expanding therapeutic relevance of this pathway. Indeed, results from early phase clinical trials already indicate that a subset of patients with advanced tumors derive benefit from FGFR targeted therapies. FGFR gene aberrations and FGFR gene rearrangements are relatively rare in solid malignancies. The recently described FGFR3-TACC3 fusion protein has a constitutively active tyrosine kinase domain and promotes aneuploidy. We summarize the prevalence data on FGFR3-TACC3 fusions among different histological tumor types and the preliminary evidence that this rearrangement represents a targetable molecular aberration in some patients with solid tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available